Insulet Recalls Omnipod Devices Over Dosing Defect
Insulet is conducting a voluntary correction of seven million insulin pump pods due to a manufacturing defect that may cause under-delivery of medication. The company expects to incur up to 50 million dollars in related costs this year.
Xurve View
洞察:
Xurve View
Insulet Corp issued a voluntary correction for 7 million insulin pods following a manufacturing defect that could cost the company $50 million. The defect affects 8.5% of 2023 global production and follows a separate manufacturing correction issued in March 2023. Shares fell 8% in extended trading as investors weighed the $50 million financial hit against potential safety risks and liability.
